English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 6, 2022
Oculis 宣布刊登和發表2期臨床試驗數據 突顯眼藥滴劑 OCS-01可改善糖尿病黃斑水腫患者的黃斑厚度和視力
Oculis announces publication of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema
Tuesday, August 23, 2022
Oculis公佈II期數據抗腫瘤壞死因子(anti-TNFa)眼藥滴劑利卡明利單抗(OCS-02)可緩解嚴重干眼病患者的持續眼部不適
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
Wednesday, June 29, 2022
Oculis宣布首名患者參與OCS-01「OPTIMIZE」3期臨床試驗旨在治療白內障手術後炎症和疼痛
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery
Wednesday, March 2, 2022
Oculis 获Accure Therapeutics授权引进用于治疗青光眼的神经保护候选药物 进一步强化集团的领先眼科产品线
Oculis獲Accure Therapeutics授權引進用於治療青光眼的神經保護候選藥物 進一步強化集團的領先眼科產品線
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Tuesday, February 8, 2022
Oculis 任命 Bastian Dehmel 博士为首席临床开发官

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575